Skip to main content


Log in

Association of Resistin with Insulin Resistance and Factors of Metabolic Syndrome in North Indians

  • Original Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript


Metabolic syndrome (MetS) is a cluster of interrelated common clinical disorders. The role of resistin in insulin sensitivity and MetS is controversial till date. So, the aim of the present study was to investigate the relationship of plasma resistin levels with markers of the MetS in Indian subjects. In a case control study, total 528 subjects were selected for the study. 265 (194 male and 71 female) were cases (with MetS) and 263 (164 male and 99 female) were controls (without MetS). Required anthropometric measurements and calculations were carried out accordingly. All the Biochemical estimations were carried out according to standard protocol. Resistin level was measured by the standard protocol (By ELISA i.e. enzyme linked immunosorbent assay) as illustrated in the kit. Insulin level was also measured by the standard protocol as illustrated in the kit and insulin resistance was calculated by the standard procedures. Plasma resistin levels were significantly higher in cases compared with controls (male = 13.05 ± 4.31 vs. 7.04 ± 2.09 ng/ml; p ≤ 0.001 and female = 13.53 ± 4.14 vs. 7.42 ± 2.30 ng/ml; p ≤ 0.001). Plasma resistin levels were well correlated with waist circumference, glucose, triglycerides, waist/hip ratio, systolic and diastolic blood pressure, high density lipoprotein, total cholesterol, serum low density lipoprotein, serum very low density lipoprotein, insulin and insulin resistance. Plasma resistin levels were elevated in presence of the MetS and were associated with increased metabolic risk factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others


  1. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–12.

    Article  CAS  PubMed  Google Scholar 

  2. Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab. 2002;1:18–23.

    Article  Google Scholar 

  3. Juan CC, Au LC, Fang VS, Kang SF, Ko YH, Kuo SF, et al. Suppressed gene expression of adipocyte resistin in an insulin-resistant rat model probably by elevated free fatty acids. Biochem Biophys Res Commun. 2001;289:1328–33.

    Article  CAS  PubMed  Google Scholar 

  4. Le Lay S, Boucher J, Rey A, Castan-Laurell I, Krief S, Ferre P. Decreased resistin expression in mice with different sensitivities to a high-fat diet. Biochem Biophys Res Commun. 2001;289:564–7.

    Article  PubMed  Google Scholar 

  5. Ukkola O. Resistin—a mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinol. 2002;147:571–4.

    Article  CAS  PubMed  Google Scholar 

  6. Palanivel R, Maida A, Liu Y, Sweeney G. Regulation of insulin signalling, glucose uptake and metabolism in rat skeletal muscle cells upon prolonged exposure to resistin. Diabetologia. 2006;1:183–90.

    Article  Google Scholar 

  7. Kim KH, Lee K, Moon YS, Sul HS. A cysteine-rich adipose tissue specific secretory factor inhibits adipocyte differentiation. J Biol Chem. 2001;14:11252–6.

    Article  Google Scholar 

  8. Qi Q, Wang J, Li H, Yu Z, Ye X, Hu FB. Associations of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-aged and older Chinese. Eur J Endocrinol. 2008;159:585–93.

    Article  CAS  PubMed  Google Scholar 

  9. Sharma P, Mishra S. Metabolic syndrome: early identification prevents type II diabetes and cardiovascular disease. Indian J Clin Biochem. 2007;22(1):1–3.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Won JC, Park CY, Lee WY, Lee ES, Oh SW, Park SW. Association of plasma levels of resistin with subcutaneous fat mass and markers of inflammation but not with metabolic determinants or insulin resistance. J Korean Med Sci. 2009;24:695–700.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Sinorita H, Asdie RH, Pramono RB, Purnama LB, Asdie AH. Leptin, Adiponectin and Resistin concentration in obesity class I and II at Sardjito Hospital Yogyakarta. Acta Med Indones. 2010;42:74–7.

    PubMed  Google Scholar 

  12. Wasim H, Al-Daghri NM, Chetty R, McTernan PG, Barnett AH, Kumar S. Relationship of serum adiponectin and resistin to glucose intolerance and fat topography in South-Asians. Cardiovasc Diabetol. 2006;2:5–10.

    Google Scholar 

  13. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab. 2003;11:5452–5.

    Article  Google Scholar 

  14. Heilbronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E, et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab. 2004;4:1844–8.

    Article  Google Scholar 

  15. Pagano C, Marin O, Calcagno A, Schiappelli P, Pilon C, Milan G, et al. Increased plasma resistin in adults with Prader–Willi syndrome is related to obesity and not to insulin resistance. J Clin Endocrinol Metab. 2005;90:4335–40.

    Article  CAS  PubMed  Google Scholar 

  16. Matsuda M, Kawasaki F, Yamada K, Kanda Y, Saito M, Eto M, et al. Impact of adiposity and plasma adipocytokines on diabetic angiopathies in Japanese type 2 diabetic subjects. Diabet Med. 2004;21:881–8.

    Article  CAS  PubMed  Google Scholar 

  17. Utzschneider KM, Carr DB, Tong J, Wallace TM, Hull RL, Zraika S, et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia. 2005;48:2330–3.

    Article  CAS  PubMed  Google Scholar 

  18. Filippidis G, Liakopoulos V, Mertens PR, Kiropoulos T, Stakias N, Verikouki C, et al. Resistin serum levels are increased but not correlated with insulin resistance in chronic hemodialysis patients. Blood Purif. 2005;23:421–8.

    Article  CAS  PubMed  Google Scholar 

  19. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–16.

    Article  PubMed  Google Scholar 

  20. Ninomiya JK, L’Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004;109:42–6.

    Article  PubMed  Google Scholar 

  21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.

    Article  Google Scholar 

  22. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest. 2003;111:225–30.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. El-Shal AS, Pasha HF. Association of resistin gene polymorphisms with insulin resistance in Egyptian obese patients. Gene. 2013;515:233–8.

    Article  CAS  PubMed  Google Scholar 

  24. Kim S-K, Choe J-Y, Park S-H, Lee SW, Lee GH, Chung WT. Increased Insulin Resistance and Serum Resistin in Korean Patients with Behçet’s Disease. Arch Med Res. 2010;41(4):269–77.

    Article  CAS  PubMed  Google Scholar 

  25. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005;111:932–9.

    Article  CAS  PubMed  Google Scholar 

  26. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res. 2003;11:01–997.

    Article  Google Scholar 

  27. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab. 2003;88:4848–56.

    Article  CAS  PubMed  Google Scholar 

  28. Malo E, Ukkola O, Jokela M, Moilanen L, Kahonen M, Nieminen MS, et al. Resistin is an indicator of the metabolic syndrome according to five different definitions in the finnish health 2000 survey. Metab Syndr Relat Disord. 2011;9:203–11.

    Article  CAS  PubMed  Google Scholar 

  29. Osawa H, Tabara Y, Kawano R, Ohashi J, Ochi M, Onuma H, et al. Plasma resistin, associated with single nucleotide polymorphism −420, is correlated with insulin resistance, lower HDL, and high sensitivity CRP in the Japanese general population. Diabetes Care. 2007;30:1501–6.

    Article  CAS  PubMed  Google Scholar 

Download references


The financial assistance provided by the ICMR, New Delhi is duly acknowledged.

Conflict of interest

There is no conflict of interest exists among the authors.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Arun Kumar Singh.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singh, A.K., Tiwari, S., Gupta, A. et al. Association of Resistin with Insulin Resistance and Factors of Metabolic Syndrome in North Indians. Ind J Clin Biochem 30, 255–262 (2015).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: